8.8 C
London
Friday, November 8, 2024
HomeBusinessRipple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation...

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Date:

Related stories

Borderless Renewables Re-Emerges with Key Insights Into Decarbonised Electrification Policy Frameworks

 After a period of focused scientific research, Borderless Renewables...

Introducing the Beauty and Wellness Industry’s Best-Kept Secret: jeuje.me

 www.jeuje.me is proud to announce the upcoming launch of...

Sencore Continues to Evolve the AFN Platform with New 12G-SDI Input Option

 Sencore, a recognized leader in video delivery solutions for...

Hashgraph Online DAO: Genesis of a Fully On-Chain Internet

 Hashgraph Online DAO LLC today announces its official launch,...

Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT…

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories